产品名称
阿立哌唑, European Pharmacopoeia (EP) Reference Standard
SMILES string
Clc1c(cccc1N2CCN(CC2)CCCCOc3cc4c(cc3)CCC(=O)N4)Cl
InChI
1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)
InChI key
CEUORZQYGODEFX-UHFFFAOYSA-N
grade
pharmaceutical primary standard
API family
aripiprazole
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
正在寻找类似产品? 访问 产品对比指南
Application
Aripiprazole EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Andrea de Bartolomeis et al.
Expert opinion on pharmacotherapy, 13(14), 2027-2036 (2012-09-06)
Bipolar disorder is characterized by a complex set of symptoms, including recurrent manic, depressive or mixed episodes. Acute and long-term treatment of patients with bipolar disorder is mandatory to prevent symptom relapse and episode recurrences. Outcomes with monotherapy are often
Peter Paul De Deyn et al.
Expert opinion on pharmacotherapy, 14(4), 459-474 (2013-01-29)
Psychosis is a common and difficult to treat symptom in Alzheimer's disease (AD). It is a cause of diminished quality of life and caregiver distress. Atypical antipsychotics are frequently used for the treatment of dementia-related psychosis, despite FDA warnings because
Manit Srisurapanont et al.
Journal of psychiatric research, 62, 38-47 (2015-01-27)
Limited options are available for clozapine-resistant schizophrenia and intolerable side effects of clozapine. We conducted a systematic review of randomized-controlled trials (RCTs) to determine the efficacy and safety of aripiprazole augmentation of clozapine for schizophrenia. Electronic databases searched included PubMed
Rachel Brown et al.
The Cochrane database of systematic reviews, 12(12), CD005000-CD005000 (2013-12-19)
Bipolar disorder is a mental disorder characterised by episodes of elevated or irritable mood (manic or hypomanic episodes) and episodes of low mood and loss of energy (depressive episodes). Drug treatment is the first-line treatment for acute mania with the
Lesley Uttley et al.
PharmacoEconomics, 31(11), 981-990 (2013-10-05)
As part of its single technology process, the National Institute for Health and Care Excellence (NICE) invited the manufacturers of aripiprazole (Otsuka Pharmaceutical Co. and Bristol Myers Squibb) to submit evidence of the clinical and cost effectiveness of aripiprazole for
实验方案
Aripiprazole, an atypical antipsychotic, treats schizophrenia, bipolar disorder, and major depressive disorder.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持